hVIVO Gestione

Gestione criteri di controllo 4/4

hVIVO Il CEO è Mo Khan, nominato in Feb2022, e ha un mandato di 2.75 anni. la retribuzione annua totale è £ 621.00K, composta da 49% di stipendio e 51% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.077% delle azioni della società, per un valore di € 125.43K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 3.5 anni.

Informazioni chiave

Mo Khan

Amministratore delegato

UK£621.0k

Compenso totale

Percentuale dello stipendio del CEO	49.0%
Mandato del CEO	2.8yrs
Proprietà del CEO	0.08%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mo Khan rispetto agli utili di hVIVO?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	UK£17m
Mar 31 2024	n/a	n/a	UK£17m
Dec 31 2023	UK£621k	UK£304k	UK£16m
Sep 30 2023	n/a	n/a	UK£9m
Jun 30 2023	n/a	n/a	UK£3m
Mar 31 2023	n/a	n/a	UK£1m
Dec 31 2022	UK£592k	UK£260k	-UK£776k

Compensazione vs Mercato: La retribuzione totale di Mo ($USD 780.42K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 786.80K ).

Compensazione vs guadagni: La retribuzione di Mo è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Mo Khan (55 yo)

2.8yrs

Mandato

UK£621,000

Compensazione

Dr. Yamin Mohammed Khan, also known as Mo, serves as Chief Executive Officer at hVIVO plc (formerly known as Open Orphan Plc) since February 24, 2022 and also serves as its Director since 2022. He was Inde...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yamin Khan	CEO & Director	2.8yrs	UK£621.00k	0.077% € 125.4k
Stephen Pinkerton	CFO & Executive Director	2.1yrs	UK£274.00k	Nessun dato
Andrew Catchpole	Chief Scientific Officer	no data	Nessun dato	Nessun dato
Teja Marathe-Sarvadikar	Head of QA	2.8yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

Gestione esperta: Il team dirigenziale di CRO è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yamin Khan	CEO & Director	3.1yrs	UK£621.00k	0.077% € 125.4k
Stephen Pinkerton	CFO & Executive Director	2.1yrs	UK£274.00k	Nessun dato
Brendan Buckley	Member of Advisory Board & Non-Executive Director	no data	UK£45.00k	0.59% € 962.1k
Cathal Friel	Chairman of the Board	4.8yrs	UK£216.00k	Nessun dato
Martin Gouldstone	Independent Non-Executive Director	2.4yrs	UK£45.00k	Nessun dato
Elaine Sullivan	Independent Non-Executive Director	4yrs	UK£45.00k	Nessun dato
John Oxford	Chair of Advisory Board	4.8yrs	Nessun dato	Nessun dato

3.5yrs

Durata media

60.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRO sono considerati esperti (durata media dell'incarico 3.5 anni).

hVIVO Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

hVIVO plc, Annual General Meeting, May 13, 2024

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Less than half of directors are independent

Recent updates

hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

hVIVO plc, Annual General Meeting, May 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

Now 22% undervalued

hVIVO plc Signs £6.3 Million Human Challenge Study Model

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

Full year 2022 earnings released: UK£0.001 loss per share (vs UK£0 in FY 2021)

Forecast to breakeven in 2023

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

hVIVO plc Announces Publication of Imutex Phase I Data

Now 20% undervalued

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.018 loss in FY 2020)

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought €352k worth of stock

Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)

New 90-day high: €0.35

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

New 90-day high: €0.33

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

New 90-day high: €0.21

New 90-day high: €0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media